Last edition
News about "Beamion LUNG-1 trial "
Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC
Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.
Beamion LUNG-1 Trial | 24/10/2025 | By Dineshwori | 144
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members